Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Twin SUBLIVAC Grasses Clinical Efficacy Study.

Next Previous
Trial Profile

Twin SUBLIVAC Grasses Clinical Efficacy Study.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Allergic asthma; Grass pollen hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Sponsors HAL Allergy

Most Recent Events

  • 15 Sep 2009 Actual end date (1 Oct 2007) added as reported by ClinicalTrials.gov.
  • 15 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 23 Mar 2008 The expected completion date for this trial is now 1 Nov 2009, reported by ClinicalTrials.gov. Planned patient number also updated.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top